Vaxxinity up on start of dosing in pivotal COVID booster shot trial

Vaxxinity

28/03/2022 15:08

** Shares of Vaxxinity Inc  VAXX.O  rise 2.3% to $4.1
    ** Co begins dosing participants in late-stage trial of its
next-generation COVID-19 booster candidate  urn:newsml:reuters.com:*:nGNX5q3XkS
    ** Study is evaluating potential for UB-612 to boost
immunity against COVID-19 in people who have been fully
vaccinated with an mRNA, adenovirus vector, or inactivated virus
COVID-19 vaccine
    ** Top-line study data expected in H2 2022; if successful,
this study may support conditional approval of UB-612
    ** VAXX down ~27% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))